Login to Your Account



HCV Data Drop HGS’ Shares; ‘Not Slam-Dunk,’ Analyst Says

By Randall Osborne


Wednesday, March 15, 2006
Mixed interim data from a pair of Phase II trials with its drug for hepatitis C virus sent Human Genome Sciences Inc.’s stock down 20.3 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription